Bevacizumab Pipeline, DelveInsight\nBevacizumab Pipeline constitutes 25+ key companies continuously working towards developing 30+ Bevacizumab treatment therapies, analyzes DelveInsight. Bevacizumab Overview: Bevacizumab, marketed as Avastin, is a therapeutic agent approved for the treatment of several cancers and certain eye conditions. Extensive research has highlighted the critical role of vascular endothelial growth factor (VEGF) in supporting cancer cell growth and survival. VEGF is central to processes like angiogenesis, lymphangiogenesis, and tumor progression, making it a key target for cancer therapies. Angiogenesis-the development of new blood vessels from existing ones-is essential for tumors to expand beyond a minimal size and to spread (metastasize), as they rely on a steady blood supply for nutrients and oxygen. Among the VEGF family, VEGF-A is particularly potent, driving blood vessel formation by encouraging endothelial cell growth and migration. In cancers, VEGF is often overexpressed, correlating with enhanced vascularization, increased tumor aggressiveness, and poor clinical outcomes. In 2004, the FDA approved bevacizumab as the first antiangiogenic drug for cancer treatment. This approval marked a major shift in oncology, moving from conventional chemotherapy to targeted biologic therapies. Bevacizumab is a humanized IgG1 monoclonal antibody that binds to VEGF-A, blocking its interaction with VEGF receptors (VEGFR-1 and VEGFR-2) on endothelial cells. This disrupts VEGF-driven signaling pathways, inhibiting angiogenesis and reducing tumor blood supply-thereby slowing tumor growth and spread. Request for a detailed insights report on Bevacizumab pipeline insights https://www.delveinsight.com/report-store/bevacizumab-biosimilars-insight?utm_source=openpr&amp;utm_medium=pressrelease&amp;utm_campaign=kpr \"Bevacizumab Pipeline Insight 2025\" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Bevacizumab Therapeutics Market. Key Takeaways from the Bevacizumab Pipeline Report DelveInsight's Bevacizumab pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for Bevacizumab treatment. April 10, 2025: The FDA approved JobevneTM, a biosimilar of Avastin (bevacizumab), developed by Biocon Biologics. Key Bevacizumab companies such as Amgen/ Allergan, Bio-Thera Solutions, Biocad, Biocon/Mylan, BioIntegrator, BioXpress Therapeutics, Boehringer Ingelheim, Celltrion, Centus Biotherapeutics Limited, Coherus BioSciences, Daiichi Sankyo/ Amgen, Dr Reddy's, Gene Techno Science, Genor Biopharma, Harvest Moon Pharmaceuticals, Innovent Biologics, Kashiv BioSciences, Laboratorio Elea, mAbxience S.A, Mycenax Biotech, Outlook Therapeutics, Pfizer, R-Pharm, Reliance Life Sciences, Samsung Bioepis, Shanghai Henlius Biotech, Tanvex Biopharma, Zhejiang Teruisi Pharmaceutical, Zydus Cadila, and others are evaluating new drugs for Bevacizumab to improve the treatment landscape. Promising Bevacizumab pipeline therapies in various stages of development include Mvasi (Amgen), Bryxta (Zydus), HD204 (Prestige BioPharma), GB 222 (Genor Biopharma), and others. Bevacizumab Pipeline Analysis The report provides insights into: The report provides detailed insights into the key companies that are developing therapies in the Bevacizumab Market. The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Bevacizumab treatment. It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Bevacizumab market. Download our free sample page report on Bevacizumab pipeline insights https://www.delveinsight.com/sample-request/bevacizumab-biosimilars-insight?utm_source=openpr&amp;utm_medium=pressrelease&amp;utm_campaign=kpr Bevacizumab Marketed Drugs Mvasi - Amgen Mvasi is a VEGF inhibitor that functions as a biosimilar to Avastin (bevacizumab). It received approval from the U.S. FDA for the treatment of various cancers, becoming the first cancer biosimilar approved in the United States. Like Avastin, Mvasi targets and inhibits VEGF to disrupt tumor angiogenesis. Bryxta - Zydus Bryxta is a recombinant humanized monoclonal antibody composed of 1,337 amino acids and produced. It works by binding to VEGF, preventing it from interacting with VEGF receptors-VEGFR-1 (Flt-1) and VEGFR-2 (KDR)-on endothelial cells. This mechanism leads to the breakdown of existing tumor blood vessels and prevents the formation of new ones, thereby inhibiting tumor growth. Bevacizumab Emerging Drugs HD204 - Prestige Biopharma HD204 is a biosimilar of Avastin® (bevacizumab), a recombinant humanized monoclonal antibody that targets VEGF to block angiogenesis-the formation of new blood vessels crucial for tumor growth. By inhibiting VEGF, HD204 restricts the supply of oxygen and nutrients to tumors. It is under Phase III clinical evaluation (SAMSON-II) for multiple cancers, such as metastatic colorectal cancer, advanced non-small-cell lung cancer, renal cell carcinoma, cervical cancer, and other epithelial tumors. In its Phase I SAMSON-I trial, HD204 showed similar pharmacokinetics, safety, and immunogenicity to Avastin®. EG12021 - EirGenix EG12021 is an investigational bevacizumab biosimilar being developed by EirGenix. Currently in the preclinical phase, it is designed to target VEGF and inhibit angiogenesis-a critical mechanism for tumor progression and metastasis. EG12021 aims to offer a more affordable alternative to Avastin® for treating a range of solid tumors. Bevacizumab Companies There are approx. 25+ key companies which are developing the therapies for Bevacizumab. DelveInsight's report covers around 75+ products under different phases of clinical development like Late stage products (Phase III) Mid-stage products (Phase II) Early-stage product (Phase I) along with the details of Pre-clinical and Discovery stage candidates Discontinued &amp; Inactive candidates Bevacizumab pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Intravenous Subcutaneous Oral Intramuscular Bevacizumab Products have been categorized under various Molecule types such as Monoclonal antibody Small molecule Peptide Download Sample Pages to Get an in-depth Assessment of the Emerging Bevacizumab Therapies and Key Companies: Bevacizumab Clinical Trials and advancements https://www.delveinsight.com/report-store/bevacizumab-biosimilars-insight?utm_source=openpr&amp;utm_medium=pressrelease&amp;utm_campaign=kpr Bevacizumab Pipeline Therapeutic Assessment • Bevacizumab Assessment by Product Type • Bevacizumab By Stage • Bevacizumab Assessment by Route of Administration • Bevacizumab Assessment by Molecule Type Download Bevacizumab Sample report to know in detail about the Bevacizumab treatment market @ Bevacizumab Therapeutic Assessment https://www.delveinsight.com/sample-request/bevacizumab-biosimilars-insight?utm_source=openpr&amp;utm_medium=pressrelease&amp;utm_campaign=kpr Table of Content 1. Report Introduction 2. Executive Summary 3. Bevacizumab Current Treatment Patterns 4. Bevacizumab - DelveInsight's Analytical Perspective 5. Therapeutic Assessment 6. Bevacizumab Late-Stage Products (Phase-III) 7. Bevacizumab Mid-Stage Products (Phase-II) 8. Early Stage Products (Phase-I) 9. Pre-clinical Products and Discovery Stage Products 10. Inactive Products 11. Dormant Products 12. Bevacizumab Discontinued Products 13. Bevacizumab Product Profiles 14. Bevacizumab Key Companies 15. Bevacizumab Key Products 16. Dormant and Discontinued Products 17. Bevacizumab Unmet Needs 18. Bevacizumab Future Perspectives 19. Bevacizumab Analyst Review 20. Appendix 21. Report Methodology Request the Sample PDF to Get Detailed Insights About the Bevacizumab Pipeline Reports Offerings https://www.delveinsight.com/report-store/bevacizumab-biosimilars-insight?utm_source=openpr&amp;utm_medium=pressrelease&amp;utm_campaign=kpr

Bevacizumab Clinical, Companies, Therapeutic Assessment,

The article discusses the Bevacizumab pipeline, highlighting 25+ companies developing 30+ therapies for cancer treatment. It details FDA approval of JobevneTM (a biosimilar of Avastin) by Biocon Biologics in April 2025, and outlines clinical trials for biosimilars and novel therapies like Mvasi (Amgen) and HD204 (Prestige Biopharma). The report also categorizes therapies by route of administration, molecule type, and development stage.